Ardelyx, Inc. filings document a commercial-stage biopharmaceutical company with U.S. product revenue from IBSRELA and XPHOZAH and development activity centered on tenapanor and NHE3 inhibition. Form 8-K reports cover quarterly operating results, preliminary product sales, cash and investment updates, Regulation FD presentation materials, and other material-event disclosures tied to the company’s commercial and clinical programs.
Ardelyx proxy materials describe annual meeting proposals, director elections, say-on-pay matters, auditor ratification, executive compensation, board structure, and stockholder voting mechanics. Additional current reports record officer appointments, executive transitions, transition and separation agreements, compensatory arrangements, governance matters, and disclosure controls relevant to the company’s public-company reporting obligations.
ARDELYX, INC. executive Laura A. Williams reported automatic sales of company common stock tied to restricted stock unit (RSU) vesting. On February 20, 2026, she sold 7,192 shares at $5.865 and 984 shares at $5.7138 in open-market transactions. A footnote explains these were “sell-to-cover” transactions required by the RSU grant terms to cover withholding taxes upon vesting, rather than discretionary sales. Following these sales, she continued to hold over four hundred thousand Ardelyx shares directly.
ARDELYX, INC. Chief Financial Officer Susan Hohenleitner reported an automatic tax-related sale of company stock. On February 20, 2026, she sold a total of 2,033 shares of common stock in open-market transactions, at prices of $5.865 and $5.7138 per share. According to a footnote, these sales were an automatic sell-to-cover triggered by vesting restricted stock units and were made solely to cover withholding taxes. After these transactions, she directly owned 230,533 shares of Ardelyx common stock.
Ardelyx, Inc. executive Brady James Parker, the Chief Human Resources Officer, reported selling a total of 2,543 shares of common stock on February 20, 2026 in open-market transactions at prices of $5.865 and $5.7138 per share.
According to the footnote, these sales were an automatic sell-to-cover triggered upon the vesting of restricted stock units and were executed solely to cover applicable withholding taxes. After the transactions, Parker directly owned 262,912 Ardelyx shares.
Ardelyx, Inc. officer Mike Kelliher reported automatic sales of company common stock tied to vested restricted stock units. On February 20, 2026, he sold a total of 9,595 shares in open-market transactions at prices around $5.71–$5.87 per share.
According to the footnote, these were “automatic sell-to-cover” transactions required under the original RSU grant terms and were executed solely to cover withholding taxes, rather than discretionary sales. After these transactions, Kelliher directly holds 364,666 shares of Ardelyx common stock.
ARDELYX, INC. President & CEO Michael Raab reported open-market sales of a total of 45,982 shares of common stock on February 20, 2026, at prices around $5.70 to $5.87 per share. According to the filing, these sales were executed pursuant to an automatic sell-to-cover feature tied to restricted stock unit vesting and were made solely to cover applicable withholding taxes.
After these transactions, Raab directly holds 1,856,988 shares as trustee of the Michael G. Raab Living Trust dated July 25, 2012, and also has indirect ownership of 24,364 and 1,000 shares through trusts established for his children.
Ardelyx, Inc. Chief Commercial Officer Eric Duane Foster reported open-market sales of a total of 10,439 shares of common stock on February 20, 2026, at prices between $5.7003 and $5.865 per share. According to the footnote, these trades were executed automatically to sell shares upon restricted stock unit vesting solely to cover withholding taxes. After these transactions, he directly owned 425,970 Ardelyx common shares.
ARDX filed an amended Form 144/A disclosing a proposed sale of common stock, listing 10,388 shares tied to restricted stock unit vesting on 02/19/2026. The filing also reports a prior sale by Joseph James Reilly of 11,086 shares on 11/21/2025.
Laura A. Williams reports proposed sale of 24,041 shares of Common Stock. The filing lists 24,041 shares associated with the vesting of restricted stock units on 02/19/2026, described as arising from services rendered.
The notice also records sales during the prior three months: 6,426 shares on 11/21/2025 for $35,580.12 and 50,000 shares on 01/08/2026 for $348,900.00. The broker listed is Morgan Stanley Smith Barney LLC.
ARDX submitted a Form 144 reporting proposed sales of Common Stock. The filing lists 11,800 shares, notes 24,986 shares tied to the vesting of restricted stock units on 02/19/2026, and discloses a prior sale of 5,560 shares on 11/21/2025.
ARDX affiliate filed a notice to sell common stock. The filing identifies the vesting of 10,388 restricted stock units on 02/19/2026 as the source of securities to be sold. The filing also records a prior sale of 11,086 shares on 11/21/2025 for $61,382.07.